Pfizer's Ghost at the Merck-Schering Banquet
Executive Summary
Like Banquo's ghost at Macbeth's table, Pfizer Inc. haunts the new collaboration between Merck & Co. Inc. and Schering-Plough Corp. Indeed, without Pfizer, these companies may never have gotten together at all in this innovative co-development and co-promotion alliance which serves both as a patent-extension strategy and an alternative to mergers.
You may also be interested in...
Schering-Plough, Novartis and Foradil: Measuring the Need for New Products
Schering's willingness to take over the marketing responsibilities for Novartis's Foradil respiratory drug, which has been largely superseded by combination products, to some degree measures the depths of Schering's troubles. But it also indicates the kinds of competition small-company in-licensers are likely to face. A whole industry of in-licensing focused players has grown up to sell the non-core products of Big Pharma: if Schering is any indication, the competition for these products is likely to get even more intense.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.